Evidence map›Paper›PMID 41372485›Full record

ArticleOncogene2026

Role of a transmembrane protein, epithelial membrane protein 1, in the pathogenesis of pancreatic ductal adenocarcinoma.

Akihisa Ohno, Nao Fujimori, Kazuhide Matsumoto, Shojiro Haji, Osamu Sugahara, Ayumu Takeno, Takeo Yamamoto, Akihiko Suenaga, Shotaro Kakehashi, Takahiro Ueda and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Akihisa OhnoDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID http://orcid.org/0000-0003-1372-166X
Nao Fujimori *Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. fujimori.nao.239@m.kyushu-u.ac.jp.
Kazuhide MatsumotoDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shojiro HajiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID http://orcid.org/0000-0003-3651-2836
Osamu SugaharaAnticancer Strategies Laboratory, Institute of Science Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-4196-209X
Ayumu TakenoDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takeo YamamotoDepartment of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Akihiko SuenagaDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Shotaro KakehashiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takahiro UedaDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Masatoshi MurakamiDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Katsuhito TeramatsuDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Keijiro UedaDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Takamasa OonoDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoshinao OdaDepartment of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Keiichi I NakayamaAnticancer Strategies Laboratory, Institute of Science Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-7185-1529
Yoshihiro Ogawa *Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ogawa.yoshihiro.828@m.kyushu-u.ac.jp.

Funding

Daiwa Securities Health Foundation GAKF800710MEXT | Japan Society for the Promotion of Science (JSPS) JP20K17023MEXT | Japan Society for the Promotion of Science (JSPS) JP22H04993MEXT | Japan Society for the Promotion of Science (JSPS) JP23K15013MEXT | Japan Society for the Promotion of Science (JSPS) JP23K19514MEXT | Japan Society for the Promotion of Science (JSPS) JP25K11254Mochida Memorial Foundation for Medical and Pharmaceutical Research GAKF800717
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has two subtypes: the "classical/progenitor" type and "basal-like/squamous" type, the latter of which has poor clinical outcomes with no effective treatment strategies. We aimed to elucidate the role of epithelial membrane protein 1 (EMP1) in PDAC and its potential as a therapeutic target, particularly in aggressive disease such as "basal-like/squamous" type of PDAC. We examined the association of EMP1 expression using patient-derived organoids (PDOs) of human PDAC, K-RAS

Indexed as

Carcinoma, Pancreatic DuctalMembrane GlycoproteinsPancreatic NeoplasmsAnimalsCell Line, TumorCell ProliferationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMiceNeoplasm ProteinsReceptors, Cell Surfaceepithelial membrane protein-1Membrane GlycoproteinsNeoplasm ProteinsReceptors, Cell Surface

Identifiers

PMID41372485

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.